What was recalled
This page synthesizes the regulatory and biochemical framework around vitamin K supplementation in commercial pet food. Vitamin K functions as a cofactor for gamma-glutamyl carboxylase, an enzyme that activates clotting factors and bone matrix proteins by carboxylating specific glutamate residues. The carboxylated proteins acquire calcium-binding capacity required for biological function. Three vitamin K forms participate in this pathway. Phylloquinone (K1) is the plant-derived form, absorbed efficiently from dietary leafy greens and used for hepatic coagulation factor activation. Menaquinone (K2) includes multiple subtypes (MK-4 through MK-13) varying in carbon-chain length; MK-4 is animal-tissue-derived, MK-7 and longer chains are bacterial-fermentation-derived. K2 forms preferentially activate extra-hepatic vitamin K-dependent proteins (osteocalcin in bone, matrix Gla protein in vascular tissue). Menadione (K3) is a synthetic precursor lacking the isoprenoid side chain; biological activity requires post-absorption alkylation to MK-4. Conversion efficiency in dogs and cats is well established but variable across individual animals.
AAFCO Nutrient Profiles set vitamin K requirements as needed for puppies and growing dogs (no quantified minimum for adult dogs since gut bacterial synthesis is assumed adequate). Feline minimums are set as a function of dietary fish content (fish-based diets containing trimethylamine oxide and historical concerns about anticoagulant fish-feeding warrant supplementation). Most commercial pet food includes vitamin K supplementation as a precautionary measure even when not strictly required by AAFCO. Menadione is the dominant supplementation form due to cost: MSB and MNB are produced at scale for animal feed at $5-15 per kg of finished pet food premix, versus $50-150 per kg for K1 phylloquinone or K2 menaquinone alternatives.
Why it was recalled
The structural controversy has three layers. Layer one — human vs animal regulatory divergence: menadione (K3) is banned for direct human dietary use by FDA, Health Canada, and EFSA due to safety concerns including hemolytic anemia, hepatotoxicity, and oxidative stress at high dose. The bans apply to dietary supplements and infant formula. The same compound is permitted in animal feed at AAFCO-approved levels. The regulatory divergence reflects the cost-effectiveness consideration in livestock feed (where individual-animal optimization is secondary to herd-level economics) but applies equally to companion-animal pet food (where individual-pet optimization is the consumer expectation).
Layer two — pet owner awareness gap: "vitamin K" appears on most commercial pet food ingredient decks as either "menadione sodium bisulfite complex", "menadione nicotinamide bisulfite", or simply "vitamin K supplement". Consumers reading ingredient labels rarely distinguish K3 (menadione) from K1 (phylloquinone) or K2 (menaquinone). Brand customer service inquiries typically reveal menadione as the source form, but few owners pursue the inquiry. Premium and natural-positioning brands that use K1 or K2 alternatives rarely highlight the distinction in marketing, missing an opportunity for differentiation.
Layer three — emerging K2 research relevance: human nutrition research on vitamin K2 (particularly MK-7) suggests benefits for vascular calcification reduction, bone density maintenance, and cardiovascular outcomes that exceed K1 alone. The research is at an early stage in companion animals but the biological framework (carboxylation of extra-hepatic vitamin K-dependent proteins including matrix Gla protein in vasculature) applies across mammalian species. Senior dogs and cats with cardiovascular disease, chronic kidney disease, or osteoporosis risk may benefit from K2 supplementation beyond what menadione provides. The clinical evidence in veterinary nutrition is preliminary; the biological framework is well established.
Health risks for your pet
The health-risk profile of menadione supplementation in commercial pet food is debated. At AAFCO-approved levels, menadione is considered safe by AAFCO and FDA-CVM: chronic toxicity studies in dogs and cats at typical pet food concentrations have not demonstrated acute adverse effects. The concern from human nutrition research applies to high-dose menadione (>100x AAFCO levels), producing hemolytic anemia from oxidative damage to erythrocyte membranes, hepatotoxicity from reactive oxygen species, and oxidative stress markers in tissue. Whether chronic low-dose menadione at AAFCO levels produces subclinical oxidative-stress contribution over multi-year feeding remains unresolved; the absence of evidence is not evidence of absence.
K1 phylloquinone and K2 menaquinone have not demonstrated toxicity at any clinically relevant dose in human or animal studies. The biological forms with the established safety profile cost more and are biologically active without conversion. Vitamin K antagonist toxicity (anticoagulant rodenticide poisoning, accidental warfarin exposure) is a separate clinical concern; vitamin K1 phylloquinone is the treatment of choice for these emergencies and is the preferred form for therapeutic veterinary use even when menadione is the dietary supplement form. The treatment preference for K1 phylloquinone in clinical veterinary medicine alongside menadione dominance in dietary supplementation reflects a structural inconsistency in the regulatory framework.
What to do if you bought affected product
Pet owners can manage vitamin K source concerns through several practical approaches: (1) inspect ingredient deck for "menadione sodium bisulfite complex" or "menadione nicotinamide bisulfite" — these are K3 menadione forms; "phylloquinone" or "K1" indicates the plant-source form, "menaquinone" or "K2" indicates the bacterial/animal form; (2) premium and natural-positioning brands increasingly use K1 or K2 alternatives; contacting brand customer service to ask about vitamin K source form reveals the brand-level commitment; (3) senior dogs and cats with cardiovascular disease, chronic kidney disease, or osteoporosis risk may benefit from veterinary-directed K2 supplementation beyond dietary menadione; discuss with veterinarian and cardiologist or internist when indicated; (4) do not add over-the-counter K1 or K2 supplements without veterinary direction; total vitamin K intake should be managed at the population level by formulation rather than at the individual level by uncoordinated supplementation; (5) brand transparency request — the willingness to disclose vitamin K source form is itself a transparency signal; brands declining to disclose are signaling lower transparency across other formulation decisions. The broader menadione synthetic vitamin K3 framework covers the menadione-specific concerns in depth; this page focuses on the K1 phylloquinone alternative.
How this affects KibbleIQ’s grade
The KibbleIQ rubric v15 awards scoring credit for K1 phylloquinone or K2 menaquinone supplementation over K3 menadione per our published methodology, since the alternative forms carry better safety margins and the menadione human-use ban reflects regulatory concern at high dose that may extend to chronic low-dose exposure. The rubric does not penalize menadione at AAFCO-approved levels since AAFCO and FDA-CVM consider it safe at commercial concentrations. Pet owners optimizing for senior pets, cardiovascular-disease-risk populations, and chronic-kidney-disease populations should prioritize brands using K1 or K2 alternatives; the cost differential at the brand level (3-10x for the supplement, fractional cost at the bag level) makes this a reasonable upgrade for premium-positioned commercial formulations. The biological framework for K2-specific benefits in extra-hepatic carboxylation continues to evolve.